Form 4: Tyra Biosciences COO Daniel Bensen Sells Shares Under 10b5-1 Trading Plan

Daniel Bensen, Chief Operating Officer of Tyra Biosciences, sold shares of common stock on March 6 and 7, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Daniel Bensen, the Chief Operating Officer of Tyra Biosciences, sold shares of the company's common stock on March 6 and March 7, 2024.
• The sales were executed under a Rule 10b5-1 trading plan adopted on December 7, 2022.
• On March 6, 1,733 shares were sold at a weighted average price of $20.092, with individual sale prices ranging from $20.00 to $20.39.
• On March 7, 68 shares were sold at $20 per share.
• Following these transactions, Bensen directly owns 431,883 shares of Tyra Biosciences common stock.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing detailing stock sales by an executive. It doesn't inherently convey positive or negative sentiment.

Industry Context

Sales by company insiders are a normal part of corporate activity. Investors often monitor these transactions for signals about a company's prospects, but sales under 10b5-1 plans are typically pre-scheduled and may not reflect the insider's current outlook.

Stakeholder Impact

• The stock sale may have a minor impact on shareholders, potentially creating slight downward pressure on the stock price in the short term.

Key Dates